Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 3:32 pm Purchase |
2021-12-31 | 13G | Addex Therapeutics Ltd ADXN |
GOLDMAN SACHS GROUP INC GS |
150,349 6.100% |
150,349 (New Position) |
Filing History |
| 2022-02-14 1:57 pm Purchase |
2021-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CREDIT SUISSE FIRST BOSTON | 93,830 4.950% |
118 (+0.13%) |
Filing History |
| 2022-02-11 4:48 pm Purchase |
2021-12-31 | 13G | Addex Therapeutics Ltd ADXN |
New Leaf Biopharma Opportunities I L.P. | 118,315 4.500% |
2,500 (+2.16%) |
Filing History |
| 2022-01-10 1:15 pm Unchanged |
2021-12-16 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 20.400% |
0 (Unchanged) |
Filing History |
| 2021-09-08 06:01 am Purchase |
2021-08-30 | 13D | Addex Therapeutics Ltd ADXN |
Dyer Timothy Mark | 181,549 9.730% |
38,172 (+26.62%) |
Filing History |
| 2021-02-16 4:19 pm Purchase |
2020-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CAXTON CORP | 115,815 8.400% |
115,815 (New Position) |
Filing History |
| 2021-02-12 3:53 pm Purchase |
2020-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CREDIT SUISSE FIRST BOSTON | 93,712 5.710% |
93,712 (New Position) |
Filing History |
| 2021-02-10 5:30 pm Purchase |
2020-12-31 | 13G | Addex Therapeutics Ltd ADXN |
New Leaf Biopharma Opportunities I L.P. | 115,815 7.100% |
115,815 (New Position) |
Filing History |
| 2021-01-21 6:47 pm Purchase |
2021-01-11 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 21.500% |
385,230 (New Position) |
Filing History |
| 2020-11-03 4:10 pm Purchase |
2020-10-25 | 13D | Addex Therapeutics Ltd ADXN |
Dyer Timothy Mark | 143,377 8.730% |
143,377 (New Position) |
Filing History |